Popular Articles

Mum Is Key To Solving Obesity
One of the UK"s leading weight loss organisations has backed calls for changes to the way that obesity is being tackled nationally after a new study suggested that children learn unhealthy lifestyle behaviour from parents of the same gender.
generic viagra online
Sleep And Weight Gain: A Molecular Link
There appears to be a link between sleep and weight control, with some studies indicating that sleep disruption can increase weight gain and others that diet affects sleep. Victor Uebele and colleagues, at Merck Research Laboratories, West Point, have now provided further evidence to support this association by showing that T-type calcium channels regulate body weight maintenance and sleep in mice. These data suggest that sleep and circadian treatment approaches may be of benefit in the fight against obesity.
News of the day
GenWay Biotech Obtains CLIA Certification
GenWay Biotech, Inc., a US-based diagnostic company has become CLIA certified and received a California lab license. Their license currently permits the testing of immunological biomarkers. This is a very important step in the direction of commercialization of the novel innovative diagnostic tests currently being developed at GenWay. In upcoming weeks, GenWay will add new cancer biomarker tests to their portfolio as well as several infectious diseases such as sexual transmitted diseases. GenWay is seeking to obtain CAP accreditation by the end of the year.
Health Insurance

WHO Approves Second HPV Vaccine

The WHO announced Thursday it had approved a second cervical cancer vaccine, opening "U.N. agencies and partners [to] now officially buy millions of doses of the vaccine for poor countries worldwide," where an estimated 80 percent of the 280,000 annual deaths from cervical cancer occur each year, the AP/Google.com reports (7/9). Cervarix, produced by GlaxoSmithKline (GSK), prevents HPV infection, which can cause cervical cancer. Cervarix, joins Merck"s Gardasil, in receiving the "green light" from the WHO, Reuters reports. "WHO "prequalification" is necessary for U.N. agencies and the non-profit GAVI Alliance to purchase the vaccine, and Glaxo said on Thursday it hoped the move would help speed access to Cervarix globally," Reuters writes (Hirschler, 7/9) - which officials say will save "tens of thousands of lives," according to AP/Google.com (7/9). "We"re very eager to offer women in developing countries these vaccines because without early screening, they are arguably more vulnerable to cervical cancer," Dan Thomas, a spokesman for GAVI, said, according to Reuters (7/9). However, cost arrangements have yet to be settled, Dow Jones Newswires/Wall Street Journal reports (Stovall, 7/9). Reuters reports that GAVI is in talks with GSK and Merck in hopes of bringing the cost of the vaccine down for developing countries (7/9). AP/Google.com writes: "In the West, the vaccines typically cost about $360 for a three-shot dose - which is far too expensive for poor countries, Thomas said" (7/9). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):